C8138
氯丙嗪 盐酸盐
≥98% (TLC), powder, D2 dopamine receptor antagonist
别名:
2-氯-10-(3-二甲氨基丙基)吩噻嗪 盐酸盐, CPZ, 氯普马嗪
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C17H19ClN2S · HCl
化学文摘社编号:
分子量:
355.33
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
200-701-3
MDL number:
Beilstein/REAXYS Number:
3779989
产品名称
氯丙嗪 盐酸盐, ≥98% (TLC)
Quality Level
assay
≥98% (TLC)
form
powder
mp
194-196 °C
solubility
water: 50 mg/mL
originator
GlaxoSmithKline
SMILES string
Cl[H].CN(C)CCCN1c2ccccc2Sc3ccc(Cl)cc13
InChI
1S/C17H19ClN2S.ClH/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20;/h3-4,6-9,12H,5,10-11H2,1-2H3;1H
InChI key
FBSMERQALIEGJT-UHFFFAOYSA-N
Gene Information
human ... DRD2(1813), DRD3(1814), DRD4(1815), HRH1(3269), HTR2A(3356)
Application
Chlorpromazine hydrochloride has been used:
- as an antagonists for calmodulin kinase
- as a medium supplement to test its cytotoxic effects in human lung microvascular endothelial cells (HMVEC-L)
- as an inhibitor of clathrin-mediated endocytosis in RAW 264.7 cells
在血红蛋白和过氧化物酶的微量测定中替代联苯胺、邻联茴香胺和邻联甲苯胺。
Biochem/physiol Actions
吩噻嗪类抗精神病药;D2 多巴胺受体拮抗剂，H1 组胺受体拮抗剂;抑制钙调蛋白依赖性环核苷酸磷酸二酯酶和一氧化氮合成酶的活化。
氯丙嗪表现出对白血病细胞的细胞毒性和抗增殖活性，但是不会影响正常淋巴细胞的活力。
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under 氯丙嗪 盐酸盐
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 1 Inhalation - Acute Tox. 3 Oral
存储类别
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
Enhanced uptake and siRNA-mediated knockdown of a biologically relevant gene using cyclodextrin polyrotaxane
Dandekar P, et al.
Journal of Material Chemistry B: Materials for Biology and Medicine, 3(13), 2590-2598 (2015)
Endocytic pathways used by Andes virus to enter primary human lung endothelial cells
Chiang CF, et al.
PLoS ONE, 11(10), e0164768-e0164768 (2016)
Wenquan Ou et al.
Nano-micro letters, 12(1), 90-90 (2020-04-13)
Because of enhanced efficacy and lower side effects, cancer immunotherapies have recently been extensively investigated in clinical trials to overcome the limitations of conventional cancer monotherapies. Although engineering attempts have been made to build nanosystems even including stimulus nanomaterials for
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| C8138-25G | 04061833629390 |
| C8138-100G | 04061833629383 |
| C8138-5G | 04061833521847 |